IDEXX Laboratories (NASDAQ:IDXX) had its price objective boosted by equities researchers at Stifel Nicolaus from $280.00 to $375.00 in a report issued on Thursday, BenzingaRatingsTable reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential downside of 5.72% from the company’s previous close.
Several other equities research analysts also recently issued reports on IDXX. Bank of America raised their price target on IDEXX Laboratories from $300.00 to $390.00 and gave the company a “buy” rating in a report on Monday, July 20th. TheStreet upgraded shares of IDEXX Laboratories from a “c+” rating to a “b-” rating in a research note on Thursday, April 30th. Finally, BidaskClub lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $317.14.
IDEXX Laboratories stock opened at $397.75 on Thursday. The company has a debt-to-equity ratio of 7.06, a current ratio of 0.85 and a quick ratio of 0.60. The company’s 50-day moving average is $335.38 and its 200-day moving average is $286.60. The firm has a market capitalization of $33.78 billion, a PE ratio of 79.55, a P/E/G ratio of 5.75 and a beta of 0.81. IDEXX Laboratories has a fifty-two week low of $168.65 and a fifty-two week high of $407.86.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Friday, July 31st. The company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.55. The firm had revenue of $637.20 million for the quarter, compared to the consensus estimate of $589.98 million. IDEXX Laboratories had a return on equity of 264.71% and a net margin of 17.78%. The business’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.43 earnings per share. As a group, analysts expect that IDEXX Laboratories will post 4.98 EPS for the current year.
In other IDEXX Laboratories news, Director Jonathan W. Ayers sold 13,600 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $286.07, for a total value of $3,890,552.00. Following the sale, the director now owns 810,467 shares of the company’s stock, valued at approximately $231,850,294.69. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jonathan W. Ayers sold 21,130 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $291.63, for a total value of $6,162,141.90. Following the transaction, the director now directly owns 831,597 shares of the company’s stock, valued at approximately $242,518,633.11. The disclosure for this sale can be found here. Insiders have sold 106,182 shares of company stock valued at $31,409,008 in the last ninety days. 2.53% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of IDXX. Advisors Asset Management Inc. grew its stake in shares of IDEXX Laboratories by 16.7% during the fourth quarter. Advisors Asset Management Inc. now owns 1,764 shares of the company’s stock worth $461,000 after buying an additional 253 shares during the last quarter. Sunbelt Securities Inc. bought a new position in IDEXX Laboratories in the fourth quarter valued at about $4,374,000. Pearl River Capital LLC boosted its stake in shares of IDEXX Laboratories by 769.2% during the fourth quarter. Pearl River Capital LLC now owns 904 shares of the company’s stock valued at $236,000 after purchasing an additional 800 shares in the last quarter. Macquarie Group Ltd. grew its holdings in shares of IDEXX Laboratories by 4.6% during the fourth quarter. Macquarie Group Ltd. now owns 2,931 shares of the company’s stock worth $766,000 after purchasing an additional 128 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of IDEXX Laboratories by 53.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 4,450 shares of the company’s stock valued at $1,162,000 after buying an additional 1,550 shares during the period. 88.58% of the stock is owned by hedge funds and other institutional investors.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
See Also: Basic Economics
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.